Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 2/20 | 0.49 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | PKM | P14618 | 1/20 | 0.47 |
| ▸ | CHUK | O15111 | 1/20 | 0.46 |
| ▸ | GSK3B | P49841 | 2/20 | 0.45 |
| ▸ | SIRT3 | Q9NTG7 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | GSK3A | P49840 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | GAA | P10253 | 2/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | RCE1 | Q9Y256 | 1/20 | 0.43 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | ATR | Q13535 | 2/20 | 0.41 |
| ▸ | GLA | P06280 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28308599 | 0.86 | ATR (0.45) | MAPTMEN1KMT2AGSK3BSIRT3 | |
| SCHEMBL28313914 | 0.86 | GSK3B (0.43) | MAPTMEN1KMT2AGSK3BSIRT3 | |
| SCHEMBL15432258 | 0.86 | HPGD (0.49) | HPGDMAPTMEN1KMT2APKM | |
| SCHEMBL555073 | 0.83 | NAMPT (0.48) | MAPTGSK3BSIRT3TDP1ATR | |
| SCHEMBL2033252 | 0.83 | KDM4C (0.50) | MAPTMEN1KMT2AGSK3BSIRT3 | |
| SCHEMBL30600744 | 0.83 | KDM4C (0.50) | MAPTMEN1KMT2AGSK3BSIRT3 | |
| SCHEMBL1637363 | 0.81 | ALDH1A1 (0.55) | HPGDMAPTMEN1KMT2ACHUK | |
| SCHEMBL30418934 | 0.81 | ALDH1A1 (0.55) | HPGDMAPTMEN1KMT2ACHUK | |
| SCHEMBL896640 | 0.81 | KMT2A (0.51) | HPGDMAPTMEN1KMT2ATDP1 | |
| SCHEMBL15432248 | 0.81 | KDM4E (0.51) | HPGDMAPTMEN1KMT2ACHUK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 116 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112898195-A | Synthesis method of tofacitinib intermediate | 常州锐博生物科技有限公司 | 2021-06-04 | — | — | CN | claimed |
| CN-112876410-A | Preparation method of N- (4-methylpyridine-3-yl) methyl carbamate | 南通雅本化学有限公司 | 2021-06-01 | — | — | CN | claimed |
| CN-104860872-A | Bis-(3R,4R)-1-benzyl-N,4-dimethyl piperidin-3-amine L-di-p-toluyl tartrate synthesis method | TIANJIN INST PHARM RESEARCH | 2015-08-26 | — | — | CN | claimed |
| CN-114835714-A | Preparation method of tofacitinib | 上海蓝乐鸟实业有限公司 | 2022-08-02 | — | — | CN | disclosed |
| CN-114685515-A | Preparation method of tofacitinib | 上海蓝乐鸟实业有限公司 | 2022-07-01 | — | — | CN | disclosed |
| CN-112898195-A | Synthesis method of tofacitinib intermediate | 常州锐博生物科技有限公司 | 2021-06-04 | — | — | CN | disclosed |
| CN-112898195-A | Synthesis method of tofacitinib intermediate | 常州锐博生物科技有限公司 | 2021-06-04 | — | — | CN | disclosed |
| CN-112876410-A | Preparation method of N- (4-methylpyridine-3-yl) methyl carbamate | 南通雅本化学有限公司 | 2021-06-01 | — | — | CN | disclosed |
| CN-112876410-A | Preparation method of N- (4-methylpyridine-3-yl) methyl carbamate | 南通雅本化学有限公司 | 2021-06-01 | — | — | CN | disclosed |
| CN-112876410-A | Preparation method of N- (4-methylpyridine-3-yl) methyl carbamate | 南通雅本化学有限公司 | 2021-06-01 | — | — | CN | disclosed |
| CN-112679506-A | Preparation method of tofacitinib citrate | 山东天铭医药科技有限公司 | 2021-04-20 | — | — | CN | disclosed |
| WO-2010123919-A2 | PIPERIDINE INHIBITORS OF JANUS KINASE 3 | AUSPEX PHARMACEUTICALS, LLC (US) | 2010-10-28 | — | — | WO | disclosed |
| WO-2010123919-A2 | PIPERIDINE INHIBITORS OF JANUS KINASE 3 | AUSPEX PHARMACEUTICALS, LLC (US) | 2010-10-28 | — | — | WO | disclosed |
| WO-2010014930-A2 | THERAPEUTIC AGENTS | BIOCRYST PHARMACEUTICALS, INC. (US) | 2010-02-04 | — | — | WO | disclosed |
| EP-1913000-A2 | PYRROLO[2,3-D]PYRIMIDINE DERIVATIVES; THEIR INTERMEDIATES AND SYNTHESIS | Pfizer Products Inc. (US) | 2008-04-23 | — | — | EP | disclosed |
| WO-2007012953-A2 | PYRROLO[2,3-D]PYRIMIDINE DERIVATIVES; THEIR INTERMEDIATES AND SYNTHESIS | PFIZER PRODUCTS INC. (US) | 2007-02-01 | — | — | WO | disclosed |
| US-7084277-B2 | Reacting 1-alkoxycarbonyl-3-oxo piperidine compound with an amine; reducing with reducing agent | PFIZER INC. (US) | 2006-08-01 | — | — | US | disclosed |
| EP-1572649-A2 | 3-AMINO-PIPERIDINE DERIVATIVES AND PROCESSES FOR THEIR PREPARATION | Pfizer Products Inc. (US) | 2005-09-14 | — | — | EP | disclosed |
| WO-2004046112-A2 | 3-AMINO-PIPERIDINE DERIVATIVES AND PROCESSES FOR THEIR PREPARATION | PFIZER PRODUCTS INC. (US) | 2004-06-03 | — | — | WO | disclosed |
| US-20040102627-A1 | 3-Amino-piperadine derivatives and methods of manufacture | PFIZER INC. | 2004-05-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040102627-A1 | 3-Amino-piperadine derivatives and methods of manufacture | PRMT5, SRM, CYP1B1 | HPGD 1062/4885MAPT 4130/4885MEN1 1613/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.